These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 16988515

  • 1. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.
    AIDS; 2006 Oct 03; 20(15):1941-50. PubMed ID: 16988515
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.
    HIV Med; 2005 Nov 03; 6(6):396-402. PubMed ID: 16268821
    [Abstract] [Full Text] [Related]

  • 4. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 5. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
    Szyld EG, Warley EM, Freimanis L, Gonin R, Cahn PE, Calvet GA, Duarte G, Melo VH, Read JS, NISDI Perinatal Study Group.
    AIDS; 2006 Nov 28; 20(18):2345-53. PubMed ID: 17117021
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study.
    Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R.
    Pharmacoepidemiol Drug Saf; 2009 Jul 28; 18(7):589-94. PubMed ID: 19402031
    [Abstract] [Full Text] [Related]

  • 9. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.
    Clin Ther; 2007 Jul 28; 29(7):1448-55. PubMed ID: 17825696
    [Abstract] [Full Text] [Related]

  • 10. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
    Iloeje UH, Yuan Y, L'italien G, Mauskopf J, Holmberg SD, Moorman AC, Wood KC, Moore RD.
    HIV Med; 2005 Jan 28; 6(1):37-44. PubMed ID: 15670251
    [Abstract] [Full Text] [Related]

  • 11. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ, Jang R, Louder A, Cluxton RJ.
    Pharmacotherapy; 2005 Aug 28; 25(8):1044-54. PubMed ID: 16207094
    [Abstract] [Full Text] [Related]

  • 12. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 28; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar 28; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 15. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 Mar 28; 10(1):73-81. PubMed ID: 15751765
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.
    Antivir Ther; 2003 Aug 28; 8(4):347-54. PubMed ID: 14518704
    [Abstract] [Full Text] [Related]

  • 18. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar 28; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.